Lupus & antiphospholipid syndrome
Proportion, domains, and risk factors of cognitive impairment in systemic lupus erythematosus
Study context
- Population
- Systemic lupus erythematosus (SLE) patients and non-lupus controls, January - March 2022
- Participants
- 60 vs 40
- Exposure
- SLE patients vs controls without SLE
- SLEn = 60
- No-SLEn = 40reference
- Outcome
- Proportion of cognitive impairment (CI) in SLE, defined as abnormalities in at least five of eight specific cognitive function tests (MMSE for overall assessment)
Main finding
As reported in the abstract
Proportion of CI in SLE
SLE
31.7%
Observational data: associations, not effects.
Further findings
| Outcome | aOR (95% CI) | |
|---|---|---|
| Risk of CI, SLEvs non-SLE (multivariate analysis) | 3.76 (1.217–11.621) | |
| 0.050.21520Adjusted odds ratio (log scale) |
- Risk of CI, SLE vs non-SLE (multivariate analysis) — Each additional year of age increases the risk of CI by 4.4%
- aOR 1.044 1.044 (95% CI 1.008 - 1.082)
Cognitive domains, SLE vs No-SLE
- Executive functions and verbal fluency more impaired in SLE than non-lupus
- No statistically significant differences in attention and concentration, episodic memory, working memory, calculation, visuospatial and visuoconstructive activity, or judgement
Factors associated with CI in SLE (multivariate analysis)
- Duration of corticosteroid therapy, per month: aOR
- 1.009 (95% CI 1.000-1.018)
- Duration of education, per year: aOR
- 0.857 (95% CI 0.736-0.999)
Original publication
Proportion, domains, and risk factors of cognitive impairment in systemic lupus erythematosus. Lupus. Published 15 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →